Zhe Jiang Dayang Biotech Group Co., Ltd. (SHE:003017)
China · Delayed Price · Currency is CNY 33.09
+0.56 (1.72%)
At close: Feb 13, 2026
SHE:003017 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 975.82 | 900.31 | 912.24 | 1,048 | 772.51 | 674.27 |
Other Revenue | 9.64 | 9.64 | 7.22 | 10.43 | 10.7 | 4.06 |
| 985.47 | 909.96 | 919.45 | 1,058 | 783.21 | 678.34 | |
Revenue Growth (YoY) | 12.43% | -1.03% | -13.10% | 35.10% | 15.46% | 9.10% |
Cost of Revenue | 765.83 | 738.72 | 757.87 | 913.61 | 633.26 | 514.11 |
Gross Profit | 219.64 | 171.24 | 161.58 | 144.49 | 149.95 | 164.23 |
Selling, General & Admin | 84.27 | 74.93 | 75.1 | 65.94 | 63.34 | 53.11 |
Research & Development | 34.98 | 28.78 | 39.22 | 34.06 | 27.84 | 22.33 |
Other Operating Expenses | -11.46 | -7.06 | -7.22 | -7.69 | -7.72 | -8.97 |
Operating Expenses | 107.69 | 97.73 | 105.52 | 94.08 | 83.65 | 67 |
Operating Income | 111.95 | 73.5 | 56.06 | 50.41 | 66.3 | 97.23 |
Interest Expense | -4.48 | -6.77 | -6.14 | -5.48 | -2.77 | -0.67 |
Interest & Investment Income | 8.88 | 8.85 | 10.79 | 3.49 | 11.22 | 1.23 |
Currency Exchange Gain (Loss) | 1.57 | 1.57 | 1.13 | 2.74 | -0.48 | -2.59 |
Other Non Operating Income (Expenses) | -0.38 | -1.27 | -0.6 | -0.65 | -0.1 | -0.65 |
EBT Excluding Unusual Items | 117.54 | 75.88 | 61.24 | 50.51 | 74.17 | 94.55 |
Gain (Loss) on Sale of Investments | 0.62 | 0.36 | -1.48 | 0.71 | -0.32 | 1.08 |
Gain (Loss) on Sale of Assets | -1.54 | 0.09 | -0.17 | 3.41 | 0.12 | -0 |
Asset Writedown | -20.2 | -7.96 | -17.02 | -0.19 | -1.89 | -1.73 |
Other Unusual Items | 3.13 | 3.28 | 4.41 | 3 | 4.06 | 6.35 |
Pretax Income | 99.55 | 71.64 | 46.99 | 57.45 | 76.14 | 100.26 |
Income Tax Expense | 7.42 | 7.91 | -3.02 | -23.27 | 6.13 | 8.65 |
Earnings From Continuing Operations | 92.13 | 63.74 | 50.01 | 80.73 | 70.01 | 91.61 |
Minority Interest in Earnings | 0.39 | 0.01 | - | - | - | - |
Net Income | 92.52 | 63.75 | 50.01 | 80.73 | 70.01 | 91.61 |
Net Income to Common | 92.52 | 63.75 | 50.01 | 80.73 | 70.01 | 91.61 |
Net Income Growth | 51.43% | 27.48% | -38.05% | 15.31% | -23.58% | 15.23% |
Shares Outstanding (Basic) | 80 | 81 | 81 | 81 | 84 | 66 |
Shares Outstanding (Diluted) | 81 | 82 | 81 | 82 | 84 | 66 |
Shares Change (YoY) | -0.52% | 1.62% | -0.99% | -2.93% | 26.42% | 5.68% |
EPS (Basic) | 1.15 | 0.78 | 0.62 | 0.99 | 0.83 | 1.38 |
EPS (Diluted) | 1.14 | 0.78 | 0.62 | 0.99 | 0.83 | 1.38 |
EPS Growth | 52.22% | 25.44% | -37.43% | 18.79% | -39.55% | 9.04% |
Free Cash Flow | 63.74 | 2.74 | 78.8 | -12.76 | -128.59 | -12.33 |
Free Cash Flow Per Share | 0.79 | 0.03 | 0.98 | -0.16 | -1.53 | -0.19 |
Dividend Per Share | 0.600 | 0.300 | 0.736 | 0.143 | 0.429 | 0.429 |
Dividend Growth | 33.25% | -59.24% | 415.05% | -66.66% | - | 100.00% |
Gross Margin | 22.29% | 18.82% | 17.57% | 13.66% | 19.14% | 24.21% |
Operating Margin | 11.36% | 8.08% | 6.10% | 4.76% | 8.47% | 14.33% |
Profit Margin | 9.39% | 7.00% | 5.44% | 7.63% | 8.94% | 13.51% |
Free Cash Flow Margin | 6.47% | 0.30% | 8.57% | -1.21% | -16.42% | -1.82% |
EBITDA | 178.38 | 140.95 | 124.86 | 109.8 | 110.54 | 128.53 |
EBITDA Margin | 18.10% | 15.49% | 13.58% | 10.38% | 14.11% | 18.95% |
D&A For EBITDA | 66.42 | 67.45 | 68.81 | 59.39 | 44.24 | 31.3 |
EBIT | 111.95 | 73.5 | 56.06 | 50.41 | 66.3 | 97.23 |
EBIT Margin | 11.36% | 8.08% | 6.10% | 4.76% | 8.47% | 14.33% |
Effective Tax Rate | 7.45% | 11.04% | - | - | 8.05% | 8.63% |
Revenue as Reported | 985.47 | 909.96 | 919.45 | 1,058 | 783.21 | 678.34 |
Advertising Expenses | - | 0.65 | 0.42 | 0.06 | 4.09 | 3.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.